According to a Wall Street Journal report, the preferred Covid-19 shot globally is the Pfizer-BioNTech vaccine.
Burlingame, California-based Humanigen reported positive data from the company’s Phase Ib ZUMA-19 trial of lenzilumab in patients treated with CAR-T in diffuse large B-cell lymphoma (DLBCL). Lenzilumab is being investigated for the drug compound’s ability to tamp down the hyper-immune response known as a cytokine storm.
Blood type not a Covid-19 risk factor in U.S.; inhaled asthma drug may keep mild illness from worseningAsthma, Blood Type, COVID-19 cytokine storm, COVID-19 Studies, COVID-19 Variant B.1.1.7, Covid-19 Variants, Lancet Respiratory Medicine, Novel Coronavirus, Researchers, Therapeutics, United States, Wearables
According to separate studies, blood type does not affect susceptibility to Covid-19 in U.S. patients and an inhaled steroid commonly used to treat asthma can help keep patients with mild Covid-19 from getting sicker.
CytoDyn’s Vyrologix Shortens Hospital Stays, Improves Survival in Severe Covid-19CCR5 antagonists, Clinical Data, Clinical Trials, Covid-19 Data, COVID-19 Severe Complications, Cytokine Storm, FDA, Health Canada, Hospitalized COVID-19 Patients, Immune Response, Medical Journals, Medicines and Healthcare products Regulatory Agency (MHRA), Primary Endpoints, R&D
Newly announced findings from a Phase III trial conducted by CytoDyn indicate that the use of the late-stage biotechnology company’s CCR5 antagonist candidate Vyrologix (leronlimab) was safe and improved the survival rate in critically ill hospitalized patients with coronavirus disease 2019.
Mesenchymal stem cells derived from umbilical cord tissue could help treat ARDS in Covid-19 patients, according to results of a Phase I/IIa clinical trial published by University of Miami researchers.
Humanigen and EVERSANA Announce Partnership to Support Launch and Commercialization of Lenzilumab for Treatment of COVID-19Biologics License Application (BLA), Business, Coronavirus Disease 2019 (COVID-19), Cytokine Storm, Emergency Use Authorization (EUA), Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Hospitalized COVID-19 Patients, Partnerships, Product Launches
Humanigen Inc. and EVERSANA announced that they are partnering to make lenzilumab available to hospitalized and hypoxic Covid-19 patients in the event that an Emergency Use Authorization is issued from the U.S. Food and Drug Administration and subsequent BLA.
Incyte and Novartis announced a Phase III study of Jakafi (ruxolitinib), a first-in-class JAK1/JAK2 inhibitor, failed to hit endpoints as a treatment for patients 12 and up with Covid-19 associated cytokine storm.
Novartis inked an exclusive worldwide license and collaboration deal with Australia-based Mesoblast to develop, commercialize and manufacture remestemcel-L for acute respiratory distress syndrome (ARDS), including when it is linked to Covid-19.
Veru’s Compound Shows Promise as Antiviral/Anti-Inflammatory Therapeutic for Covid-19Anti-Inflammatory, Antigens, Antivirals, Cancer, Cell Signaling, Clinical Studies, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Coronavirus Infections, Cytokine Storm, Prostate Cancer, R&D, Therapeutics, University of Tennessee
Veru Inc. is developing a dual anti-inflammatory/antiviral medication to combat severe Covid-19 infections.